Tower House Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Tower House Partners’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42,679	Closed	-$31.8M	–	4
2021 Q3	$31.8M	Hold	42,679	–	–	18.06%	4
2021 Q2	$27.5M	Sell	42,679 -8,344	-16%	-$5.08M	14.32%	4
2021 Q1	$29.1M	Sell	51,023 -23,977	-32%	-$14.2M	14.19%	4
2020 Q4	$43.7M	Sell	75,000 -15,000	-17%	-$8.54M	21.32%	4
2020 Q3	$46.4M	Buy	90,000 +5,000	+6%	+$2.53M	24.85%	3
2020 Q2	$38.4M	Sell	85,000 -50,000	-37%	-$22.1M	18.56%	3
2020 Q1	$47.3M	Sell	135,000 -28,379	-17%	-$10.4M	34.87%	1
2019 Q4	$60.5M	Sell	163,379 -26,621	-14%	-$9.39M	43.05%	1
2019 Q3	$63.2M	Sell	190,000 -10,000	-5%	-$3.26M	52.68%	1
2019 Q2	$62.5M	Buy	200,000 +11,795	+6%	+$3.53M	67.3%	1
2019 Q1	$57.5M	Sell	188,205 -36,795	-16%	-$9.93M	63.89%	1
2018 Q4	$52.2M	Buy	+225,000	New	+$60.4M	100%	1

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Tower House Partners's BIO Position: Q4 2021 in Review

Tower House Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2021, closing a stake of 42,679 shares — an estimated $31.8M sold.

Tower House Partners first reported a position in BIO in Q4 2018 and held it in 12 quarters. The position peaked at $63.2M in Q3 2019. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

Tower House Partners reported no remaining Bio-Rad Laboratories Class A position as of Q4 2021 after selling out during the quarter.
Tower House Partners sold 42,679 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $31.8M.
Tower House Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2018 and held it in 12 quarters.
Tower House Partners's Bio-Rad Laboratories Class A position peaked at $63.2M in Q3 2019.
533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Tower House Partners's 13F filing for Q4 2021, filed 14 Feb 2022.